TGTX MEXC RealStocks
Own real TGTX shares through MEXC's regulated brokerage partner.
Suitable for long-term holding.
- Own the actual shares
- Receive dividends and voting rights
- Buy fractional shares starting at $1
Last updated: 2026-11-19 09:12:40. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
TG Therapeutics, Inc. (TGTX) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $66.43, with a market capitalization of $9.48B and a P/E ratio of 89.37. Over the past 52 weeks, its price has ranged from $26.76 to $68.03. This page covers its latest market performance, valuation, price trends and company information.
$9.48B | |
$65.83 | |
$66.43 | |
$65.83 | |
$66.12 | |
233.00 | |
1.92M | |
89.37 | |
$68.03 | |
$26.76 | |
-- | |
2026-09-30 |
TG Therapeutics, Inc. (TGTX) is trading at $66.43 in pre-market trading as of 2026-11-19 09:06:00, up 0.46% ($0.30) from the previous close of $66.12
Pre-market trading shows how investors are pricing TGTX before the regular session opens. The current pre-market price is near the previous close, indicating positive early trading sentiment.
Over the past seven days, TG Therapeutics, Inc. (TGTX) moved from $64.26 to $66.43, representing a gain of 3.37% ($2.16).
The stock traded between $61.50 and $68.03 during the period. The latest price is near the upper end of the 7-day range, indicating moderate upward.
The average daily volume was 2.26 million shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 96.1%
TGTX is currently trading at $66.43, placing it 96.1% of the way from its 52-week low of $26.76 to its 52-week high of $68.03. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
TG Therapeutics Inc is a fully integrated, commercial-stage biotechnology company focused on acquiring, developing, and commercializing novel treatments for B-cell diseases. In addition to a research pipeline, TG Therapeutics has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) to treat adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval from several regulatory agencies outside of the U.S. for BRIUMVI to treat adult patients with RMS who have active disease defined by clinical or imaging features.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 399 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of TG Therapeutics, Inc. (TGTX) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Stock prices and market data on this page, including price changes and market status, are provided by Massive and other third-party news and data platforms. Market data may be delayed and may differ from prices on other platforms or the prices at which trades are executed on MEXC. MEXC does not guarantee the accuracy, completeness, or timeliness of third-party data. MEXC offers trading products related to TGTX, including Stocks, Tokenized Stocks, and Stock Futures.
The stock price information displayed on this page is provided for reference purposes only and may be delayed or differ from real-time market data. Prices, charts, and related metrics do not constitute investment advice and should not be relied upon for trading or investment decisions. MEXC is not responsible for any losses incurred based on the stock price information provided on this page. Please refer to official market sources or consult licensed financial professionals before making any investment decisions.
Estimate the value between TGTX shares and USD.
TGTX Shares to USD
1.00 TGTX shares = 66.425 USD
Calculations are estimates based on the latest available price and are for reference only.